^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RTX-240

    i
    Other names: RTX-212, RTX-240, RTX 240, allogeneic red cell therapeutic
    Associations

    News

    Trials
    Company:
    Rubius Therap
    Drug class:
    CD137 agonist, IL-15R stimulant
    Related drugs:
    Associations

    News

    Trials
    over1year
    RTX-240 Monotherapy and in Combination With Pembrolizumab (clinicaltrials.gov)
    P1/2, N=69, Terminated, Rubius Therapeutics | No DLTs, related deaths or SAEs were reported. RTX-240 cleared circulation rapidly.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • IL15 (Interleukin 15)
    |
    Keytruda (pembrolizumab) • RTX-240
    over1year
    RTX-240 Monotherapy and in Combination With Pembrolizumab (clinicaltrials.gov)
    P1/2, N=166, Active, not recruiting, Rubius Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • IL15 (Interleukin 15)
    |
    Keytruda (pembrolizumab) • RTX-240
    2years
    RTX-240 Monotherapy and in Combination With Pembrolizumab (clinicaltrials.gov)
    P1/2, N=166, Recruiting, Rubius Therapeutics | Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jan 2023 --> Jul 2023
    Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • IL15 (Interleukin 15)
    |
    Keytruda (pembrolizumab) • RTX-240
    2years
    Phase 1 Trial of RTX-240, allogeneic red blood cells engineered to express 4-1BBL and trans-presented IL-15, in patients (Pts) with advanced solid tumors (AACR 2022)
    RTX-240 is well tolerated at all tested doses, schedules and routes. The drug leads to activation, expansion and trafficking of two target cells (memory CD8+ T cells and NK cells) into the TME, exhibits a clear dose response effect with NK cells and demonstrates preliminary evidence of anti-tumor activity. Dose escalation continues and a PD-1 inhibitor combination arm is also enrolling.1
    Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL15 (Interleukin 15)
    |
    RTX-240
    over2years
    Anti-tumor effects of RTX-240: an engineered red blood cell expressing 4-1BB ligand and interleukin-15. (PubMed, Cancer Immunol Immunother)
    RTX-240 promotes T cell and NK cell activity in preclinical models and shows efficacy and an improved safety profile. Based on these data, RTX-240 is now being evaluated in a clinical trial.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    RTX-240
    3years
    [VIRTUAL] A phase 1 trial of RTX-240, an allogeneic engineered red blood cell with cell -surface expression of 4-1BBL and trans-presented IL-15, in patients with advanced solid tumors (AACR 2021)
    RTX-240 is tolerable and leads to activation, expansion and trafficking of memory CD8+ T cells and NK cells, with preliminary evidence of anti-tumor activity. Exploration of the dose and schedule are ongoing in this study (NCT04372706).1
    Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    RTX-240